Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1986 2
1987 6
1988 6
1989 6
1990 8
1991 17
1992 11
1993 9
1994 11
1995 11
1996 13
1997 9
1998 12
1999 18
2000 15
2001 13
2002 14
2003 14
2004 10
2005 8
2006 11
2007 13
2008 15
2009 15
2010 20
2011 18
2012 13
2013 12
2014 20
2015 20
2016 8
2017 7
2018 8
2019 11
2020 18
2021 14
2022 10
2023 7
2024 17
2025 15
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Results by year

Filters applied: . Clear all
Page 1
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Nahid P, et al. Among authors: chaisson re. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10. Clin Infect Dis. 2016. PMID: 27516382 Free PMC article.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: chaisson re. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
WHO global research priorities for antimicrobial resistance in human health.
Bertagnolio S, Dobreva Z, Centner CM, Olaru ID, Donà D, Burzo S, Huttner BD, Chaillon A, Gebreselassie N, Wi T, Hasso-Agopsowicz M, Allegranzi B, Sati H, Ivanovska V, Kothari KU, Balkhy HH, Cassini A, Hamers RL, Weezenbeek KV; WHO Research Agenda for AMR in Human Health Collaborators. Bertagnolio S, et al. Lancet Microbe. 2024 Nov;5(11):100902. doi: 10.1016/S2666-5247(24)00134-4. Epub 2024 Aug 13. Lancet Microbe. 2024. PMID: 39146948 Free PMC article. Review.
Latent Mycobacterium tuberculosis infection.
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Getahun H, et al. Among authors: chaisson re. N Engl J Med. 2015 May 28;372(22):2127-35. doi: 10.1056/NEJMra1405427. N Engl J Med. 2015. PMID: 26017823 Review. No abstract available.
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Jindani A, Harrison T, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Chang VK, et al. Among authors: chaisson re. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. Nat Commun. 2024. PMID: 39477924 Free PMC article. Clinical Trial.
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.
Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PPJ, Nahid P, Dorman SE, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Brown NE, Engle ML, Nhung NV, Nsubuga P, Diacon A, Dooley KE, Chaisson RE, Swindells S, Savic RM. Xu AY, et al. Among authors: chaisson re. Am J Respir Crit Care Med. 2024 Dec 1;210(11):1358-1369. doi: 10.1164/rccm.202401-0165OC. Am J Respir Crit Care Med. 2024. PMID: 39012226 Free PMC article. Clinical Trial.
Rethinking latent TB? Think again.
Chaisson RE, Hopewell PC. Chaisson RE, et al. IJTLD Open. 2024 Aug 1;1(8):335-337. doi: 10.5588/ijtldopen.24.0336. eCollection 2024 Aug. IJTLD Open. 2024. PMID: 39131593 Free PMC article. No abstract available.
Confronting multidrug-resistant tuberculosis.
Chaisson RE, Nuermberger EL. Chaisson RE, et al. N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478. N Engl J Med. 2012. PMID: 22670908 No abstract available.
Immunotherapy for tuberculous pericarditis.
Chaisson RE, Post WS. Chaisson RE, et al. N Engl J Med. 2014 Sep 18;371(12):1155-7. doi: 10.1056/NEJMe1409356. Epub 2014 Sep 1. N Engl J Med. 2014. PMID: 25178808 No abstract available.
474 results